Um caso de Carcinoma do Pulmão de Não Pequenas Células EGFR

Abstract

Background: EGFR mutation is the most frequent in Non-Small Cell Lung Cancer and occurs mainly in women and non-smoking patients.
Clinical case: We present the case of a 51-year-old female, former light smoker, diagnosed with lung adenocarcinoma in 2014, in stage IB. She underwent surgery and adjuvant therapy. She recurred after two years with metas-tatic lung and bone disease, with EGFR exon 21 mutation. Therapy with tyrosine-kinase inhibitor (TKI) gefitinib was started and later, osimertinib. She maintained TKI therapy for three years until clinical progression. Subsequently, several lines of chemotherapy and immunotherapy were sequenced (without alteration of molecular profile and/or histological transformation).
Discussion: Resistance to TKIs is inevitable and its mechanisms are not always known; however, maintenance should be considered if there is clinical benefit, despite imaging progression. Currently chemotherapy is the subsequent therapy that is used, but new drugs are under development to be used after resistance to osimertinib.